Haemonetics Corporation (HAE)

Fixed asset turnover

		Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020
Revenue (ttm)	US$ in thousands	1,360,824	1,373,515	1,361,223	1,333,895	1,309,055	1,270,181	1,239,232	1,218,534	1,168,660	1,129,246	1,083,714	1,026,126	993,196	953,223	933,825	903,414	870,463	883,926	902,525	945,605
Property, plant and equipment	US$ in thousands	—	—	—	—	—	—	307,766	304,467	310,885	313,138	307,844	288,321	258,482	238,841	223,747	214,782	277,415	240,009	240,405	242,969
Fixed asset turnover		—	—	—	—	—	—	4.03	4.00	3.76	3.61	3.52	3.56	3.84	3.99	4.17	4.21	3.14	3.68	3.75	3.89

March 31, 2025 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $1,360,824K ÷ $—K
= —

Haemonetics Corporation's fixed asset turnover has exhibited some fluctuations over the period. The fixed asset turnover ratio indicates how efficiently the company is utilizing its fixed assets to generate revenue.

In June 2020, the fixed asset turnover was 3.89, showing that for every dollar invested in fixed assets, the company generated $3.89 in sales. The ratio slightly decreased by September 2020 to 3.75 but remained relatively stable above 3 over the subsequent quarters.

There was a notable peak in June 2021 with a fixed asset turnover of 4.21, signaling improved efficiency in asset utilization. However, the ratio declined in the following periods and stood at 3.76 in March 2023. This indicates a potential decrease in revenue generated from fixed assets.

As of September 2023, the fixed asset turnover increased to 4.03, suggesting a better utilization of fixed assets to generate revenue compared to the previous quarter. The ratio remained above 4 in subsequent periods, demonstrating efficient management of fixed assets.

The data for fixed asset turnover is unavailable for the periods beyond December 31, 2023. It is essential for Haemonetics Corporation to maintain a healthy fixed asset turnover ratio to ensure optimal use of assets and continued revenue generation.